Markets
MA Stock Indexes
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
Local Stocks
DepoMed, Inc. (NQ: DEPO)
5.480 USD  +0.080 (+1.48%)
Official Closing Price  /  Updated: 4:00 PM EDT, May 17, 2013  /  Add to My Watchlist      
View: Quote News Research
All news about DepoMed, Inc.
 
< Previous 1 2
...
14 15 16 17 18 19 20 21 Next >
Depomed Obtains Exclusive License to Gabapentin Use in Hot Flashes
October 18, 2006
from Business Wire News Releases
Depomed Completes Enrollment in Phase II Clinical Trial in Diabetic Peripheral Neuropathy With Gabapentin GR
October 05, 2006
from Business Wire News Releases
Depomed to Present at the UBS Global Life Sciences Conference
September 20, 2006
from Business Wire News Releases
Depomed to Present at the Oppenheimer Diabetes Conference
September 18, 2006
from Business Wire News Releases
New Once-Daily Oral Diabetes Treatment Glumetza(TM) Now Available
September 06, 2006
from Business Wire News Releases
Depomed to Present at the ThinkEquity Partners Growth Conference
September 05, 2006
from Business Wire News Releases
Depomed to Present at the Thomas Weisel Partners Healthcare Conference
August 31, 2006
from Business Wire News Releases
Depomed and King Pharmaceuticals Prepare for Launch of Glumetza(TM) as Timely, New ADA Guidelines Are Issued; Consensus Statement Recommends That Metformin Be Added to Lifestyle Changes as Initial Tre
August 23, 2006
from Business Wire News Releases
Depomed Announces Completion of Phase I Clinical Trial With Gastroesophageal Reflux Disease Compound; Phase IIA Clinical Trial Planned
August 15, 2006
from Business Wire News Releases
Depomed Reports Second Quarter 2006 Financial Results; Revenues Increase to $2.2 Million Compared to $428,000 in 2005
August 07, 2006
from Business Wire News Releases
Depomed Gains Greater Access to Global Pharmaceutical Companies Through Collaboration Agreement with Patheon; The Company Expands Reach to Maximize Value of Its Proprietary Technology
August 07, 2006
from Business Wire News Releases
Depomed to Present at the Bank of America Specialty Pharmaceuticals Conference
July 28, 2006
from Business Wire News Releases
Depomed to Announce Second Quarter 2006 Financial Results on Monday, August 7, 2006
July 25, 2006
from Business Wire News Releases
Depomed Takes Action to Support Momentum in ProQuin(R) XR Sales; The Company Amends Marketing Agreement with Esprit Pharma
July 24, 2006
from Business Wire News Releases
Depomed Provides Update on Esprit Pharma Agreement
July 24, 2006
from Business Wire News Releases
Depomed Names Matthew Gosling Vice President, Legal and General Counsel
July 06, 2006
from Business Wire News Releases
Depomed to Present at the C.E. Unterberg Towbin Emerging Growth Conference
July 05, 2006
from Business Wire News Releases
Depomed Unveils Data at the Endocrine Society Meeting Showing Significant Variability Between Generic Metformin Products
June 29, 2006
from Business Wire News Releases
King Pharmaceuticals and Depomed Announce Agreement to Co-Promote Glumetza(TM)
June 28, 2006
from Business Wire News Releases
Depomed Reports Dose Proportionality of Gabapentin GR at the Endocrine Society's Annual Meeting
June 26, 2006
from Business Wire News Releases
< Previous 1 2
...
14 15 16 17 18 19 20 21 Next >
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here